This Rapid Risk Assessment focuses on acellular pertussis-containing combination vaccines used in national vaccination programmes in the EU/EEA Member States.
Early in 2015, a shortage of acellular pertussis-containing vaccines was brought to the attention of ECDC. This risk assessment provides a detailed list of mitigation options available to Member States.
The Annual Epidemiological Report 2014 gives an overview of the epidemiology of communicable diseases of public health significance in Europe, drawn from surveillance information on the 52 communicable diseases and health issues for which surveillance is mandatory in the European Union and European Economic Area countries.
This report presents the outcomes of a technical workshop, organised by ECDC, to seek a consensus on a common strategy to reduce the public health burden caused by pertussis in the EU/EEA countries.
ECDC is publishing the first external quality assurance scheme (EQA) for Bordetalla pertusis PCR, participated by 21-one laboratories from 21 European Union/European Economic Area countries.
This surveillance report was prepared by EUVAC.net, which is a European surveillance network for vaccine-preventable diseases. The network collects data on surveillance systems and selected epidemiological characteristics of vaccine preventable diseases in the EU and other participating countries. It is jointly funded by ECDC and the Statens Serum Institut (Denmark).
This surveillance report was prepared by EUVAC.net, which is a European surveillance network for vaccine-preventable diseases. The network collects data on surveillance systems and selected epidemiological characteristics of vaccine preventable diseases in the EU and other participating countries. It is jointly funded by ECDC and the Statens Serum Institut (Denmark).
This surveillance report was prepared by EUVAC.net, which is a European surveillance network for vaccine-preventable diseases. The network collects data on surveillance systems and selected epidemiological characteristics of vaccine preventable diseases in the EU and other participating countries. It is jointly funded by ECDC and the Statens Serum Institut (Denmark).